ciprofloxacin has been researched along with Infections, Proteus in 29 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 9.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "The clinical efficacy and tolerability of ciprofloxacin orally administered at the dosage of 250 mg twice a day was evaluated in 25 patients affected by acute bacterial pharyngotonsillitis." | 9.06 | Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "We evaluated the clinical features of ciprofloxacin-resistant Proteus mirabilis bacteremia and risk factors for ciprofloxacin resistance." | 7.77 | Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia. ( Chung, DR; Ha, YE; Joo, EJ; Kang, CI; Lee, NY; Peck, KR; Sohn, KM; Song, JH, 2011) |
| "Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa." | 7.67 | Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 5.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "The clinical efficacy and tolerability of ciprofloxacin orally administered at the dosage of 250 mg twice a day was evaluated in 25 patients affected by acute bacterial pharyngotonsillitis." | 5.06 | Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "We evaluated the clinical features of ciprofloxacin-resistant Proteus mirabilis bacteremia and risk factors for ciprofloxacin resistance." | 3.77 | Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia. ( Chung, DR; Ha, YE; Joo, EJ; Kang, CI; Lee, NY; Peck, KR; Sohn, KM; Song, JH, 2011) |
| "Five antimicrobial agents, ciprofloxacin, ticarcillin, piperacillin, aztreonam and gentamicin, were compared both in vitro (MIC's, time-kill studies) and in vivo, in the treatment of experimental Proteus mirabilis pyelonephritis in mice." | 3.67 | Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice. ( Maclaren, DM; Peerbooms, PG, 1987) |
| "Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa." | 3.67 | Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986) |
| " Eight adverse effects were observed in five patients and treatment had to be discontinued in one case." | 2.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "Preseptal cellulitis is a serious ocular condition that--if left untreated--has the potential to cross the septal barrier, spread to the posterior orbit, and may result in fatal complications." | 2.40 | Preseptal cellulitis secondary to Proteus species: a case report and review. ( Gabriel, HM; Sears, JM; Veith, J, 1999) |
| "An 11-year-old boy, a known case of lamellar ichthyosis, presented with microbial keratitis." | 1.35 | Microbial keratitis in a case of lamellar ichthyosis. ( Chaurasia, S; Das, S; Ramamurthy, B, 2008) |
| "Ciprofloxacin (CIP) was the least active agent tested (MIC90 4 microg/ml; 86% susceptible)." | 1.31 | Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. ( Jones, RN; Mutnick, AH; Turner, PJ, 2002) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.69) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 7 (24.14) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Zong, Z | 1 |
| Partridge, SR | 1 |
| Iredell, JR | 1 |
| Wang, M | 2 |
| Guo, Q | 1 |
| Xu, X | 1 |
| Wang, X | 1 |
| Ye, X | 1 |
| Wu, S | 1 |
| Hooper, DC | 1 |
| Hamid, K | 1 |
| Hamza, M | 1 |
| Naim, T | 1 |
| Shahid, M | 1 |
| Hsu, JL | 1 |
| Abokhalil, RN | 1 |
| Elkhatib, WF | 1 |
| Aboulwafa, MM | 1 |
| Hassouna, NA | 1 |
| Soliman, AM | 1 |
| Shimamoto, T | 2 |
| Nariya, H | 1 |
| Nagiah, S | 1 |
| Badbess, R | 1 |
| Kwiecińska-Piróg, J | 1 |
| Bogiel, T | 1 |
| Gospodarek, E | 1 |
| Ullah, O | 1 |
| Khan, A | 1 |
| Ambreen, A | 1 |
| Ahmad, I | 1 |
| Akhtar, T | 1 |
| Gandapor, AJ | 1 |
| Khan, AM | 1 |
| Bergogne-Bérézin, E | 1 |
| Weckwerth, PH | 1 |
| de Magalhães Lopes, CA | 1 |
| Duarte, MA | 1 |
| Weckwerth, AC | 1 |
| Martins, CH | 1 |
| Neto, DL | 1 |
| de Aguiar, HF | 1 |
| Kanayama, A | 1 |
| Iyoda, T | 1 |
| Matsuzaki, K | 1 |
| Saika, T | 1 |
| Ikeda, F | 1 |
| Ishii, Y | 1 |
| Yamaguchi, K | 1 |
| Kobayashi, I | 1 |
| Sohn, KM | 1 |
| Kang, CI | 1 |
| Joo, EJ | 1 |
| Ha, YE | 1 |
| Chung, DR | 1 |
| Peck, KR | 1 |
| Lee, NY | 1 |
| Song, JH | 1 |
| Hu, YY | 1 |
| Cai, JC | 1 |
| Zhang, R | 1 |
| Zhou, HW | 1 |
| Sun, Q | 1 |
| Chen, GX | 1 |
| Mutnick, AH | 1 |
| Turner, PJ | 1 |
| Jones, RN | 1 |
| Sedlacek, M | 1 |
| Suriawinata, AA | 1 |
| Schoolwerth, A | 1 |
| Remillard, BD | 1 |
| Chaurasia, S | 1 |
| Das, S | 1 |
| Ramamurthy, B | 1 |
| Saito, R | 1 |
| Okugawa, S | 1 |
| Kumita, W | 1 |
| Sato, K | 1 |
| Chida, T | 1 |
| Okamura, N | 1 |
| Moriya, K | 1 |
| Koike, K | 1 |
| Fombeur, JP | 1 |
| Barrault, S | 1 |
| Koubbi, G | 1 |
| Laurier, JN | 1 |
| Ebbo, D | 1 |
| Lecomte, F | 1 |
| Sorrel, N | 1 |
| Dobler, S | 1 |
| Wilson, C | 1 |
| Senior, BW | 1 |
| Tiwana, H | 1 |
| Caparros-Wanderley, W | 1 |
| Ebringer, A | 1 |
| Sears, JM | 1 |
| Gabriel, HM | 1 |
| Veith, J | 1 |
| Naber, KG | 1 |
| Busch, W | 1 |
| Focht, J | 1 |
| Zhang, YP | 1 |
| Esposito, S | 1 |
| D'Errico, G | 1 |
| Montanaro, C | 1 |
| Marcos Sánchez, F | 1 |
| Parrilla Herranz, P | 1 |
| Celdran Gil, J | 1 |
| Durán Peréz-Navarro, A | 1 |
| Ganz, H | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Peerbooms, PG | 1 |
| Maclaren, DM | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Leigh, DA | 1 |
| Emmanuel, FX | 1 |
| Petch, VJ | 1 |
2 reviews available for ciprofloxacin and Infections, Proteus
| Article | Year |
|---|---|
[Lower urinary tract infections: bacterial epidemiology and recommendations].
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Ag | 2008 |
Preseptal cellulitis secondary to Proteus species: a case report and review.
Topics: Adult; Cellulitis; Ciprofloxacin; Diagnosis, Differential; Drainage; Eye Infections, Bacterial; Eyel | 1999 |
3 trials available for ciprofloxacin and Infections, Proteus
| Article | Year |
|---|---|
Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Earache; Female; Humans; Male; Middle A | 1994 |
Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Chronic Dis | 2000 |
Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Clinical Trials as Topic; Drug Administration Sche | 1990 |
24 other studies available for ciprofloxacin and Infections, Proteus
| Article | Year |
|---|---|
RmtC 16S rRNA methyltransferase in Australia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Australia; beta-Lactam Resistance; beta-Lactamases; beta-Lac | 2008 |
New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Proteins; Base Sequence; Conjugation, Genetic; | 2009 |
A Unique Case of Community Acquired Proteus mirabilis Meningitis.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Disease Progression; Female; Humans; I | 2022 |
Persisters of Klebsiella pneumoniae and Proteus mirabilis: A Common Phenomenon and Different Behavior Profiles.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Klebsiella Infections; Kle | 2020 |
Emergence of
Topics: Anti-Bacterial Agents; Cephalosporins; Chloramphenicol; Chromosome Mapping; Chromosomes, Bacterial; | 2019 |
Unexpected source of
Topics: Aged, 80 and over; Aneurysm, Infected; Anti-Bacterial Agents; Aortic Aneurysm, Thoracic; Bacteremia; | 2018 |
Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods.
Topics: Anti-Bacterial Agents; Biofilms; Ceftazidime; Ciprofloxacin; Female; Humans; Male; Microbial Sensiti | 2013 |
Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2016 |
Chronic suppurative otitis media in cleft palate: microorganism etiology and susceptibilities.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteria; Child; Child, Preschool; Chronic Disease; Ciprof | 2009 |
Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Ciprofloxacin; DN | 2010 |
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia.
Topics: Adult; Aged; Anti-Infective Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bac | 2011 |
Emergence of Proteus mirabilis harboring blaKPC-2 and qnrD in a Chinese Hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Ciprofloxacin; Clone | 2012 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic F | 2002 |
Ciprofloxacin crystal nephropathy--a 'new' cause of acute renal failure.
Topics: Acute Kidney Injury; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Crystallization; Duode | 2006 |
Microbial keratitis in a case of lamellar ichthyosis.
Topics: Anti-Bacterial Agents; Cefazolin; Child; Ciprofloxacin; Corneal Ulcer; Drug Therapy, Combination; Ec | 2008 |
Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; | 2007 |
Antibiotic sensitivity and proticine typing of Proteus mirabilis strains associated with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Arthritis | 1998 |
[Common pathogens in burn infection and changes in their drug sensitivity].
Topics: Amikacin; Burns; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Pro | 1991 |
[The efficacy of oral ciprofloxacin in the treatment of Proteus mirabilis infections of the lower respiratory tract].
Topics: Administration, Oral; Ciprofloxacin; Drug Evaluation; Humans; Proteus Infections; Proteus mirabilis; | 1989 |
[Gyrase inhibitor in the local treatment of the chronically infected middle ear following surgery].
Topics: Administration, Topical; Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance; Escheric | 1986 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Male; Mice; Microbial Sensitivity Tests; Proteus Infe | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Escherichia coli Infections; Female; | 1986 |